This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 6.57% and 10.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Indices Fight Back; PLTR Meets, SWKS and PARA Beat
by Mark Vickery
The Dow climbed back +408 points on the day, +1.16%, while the Nasdaq gained +84 points, +0.61%.
Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More
by Kinjel Shah
Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several drugs and may have boosted Eli Lilly's (LLY) second-quarter sales.
Incyte (INCY) Beats on Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Incyte (INCY) reports impressive Q2 earnings on strong uptake in Jakafi and Opzelura sales. The company raises the bottom end of full-year guidance, setting a new range of $2.58-$2.63 billion.
Merck (MRK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 5.07% and 4.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Results, MRK, MRNA Cancer Jab in Phase III
by Kinjel Shah
AstraZeneca (AZN), Sanofi (SNY) and AbbVie (ABBV) announce second-quarter results.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $459.32, moving -0.59% from the previous trading session.
Pharma Stock Roundup: JNJ, NVS Upbeat Q2 Results, FDA Nod to SNY & AZN RSV Antibody
by Kinjel Shah
FDA approves AstraZeneca (AZN) and Sanofi's (SNY) RSV antibody, Beyfortus. J&J (JNJ) and Novartis (NVS) announce strong second-quarter results.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $451.20, marking a +0.91% move from the previous day.
Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression
by Zacks Equity Research
Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Company News for Jul 17, 2023
by Zacks Equity Research
Companies in The News Are: C, ERIC, STT, LLY.
Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio
by Zacks Equity Research
For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Zacks Analyst Blog Highlights Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices
by Zacks Equity Research
Visa, UnitedHealth Group, Eli Lilly, Costco, Wholesale and Advanced Micro Devices are part of the Zacks top Analyst Blog .
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $440.60, moving +0.28% from the previous trading session.
Top Analyst Reports for Visa, UnitedHealth & Eli Lilly
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), UnitedHealth Group Incorporated (UNH) and Eli Lilly and Company (LLY).
Novo Nordisk (NVO) Falls on EMA Safety Review of Obesity Drugs
by Zacks Equity Research
Novo Nordisk's (NVO) important diabetes care and obesity drugs are under review by the EMA's safety committee for the risk of suicidal behavior with its use. The stock falls 3%.
Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug
by Zacks Equity Research
Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.
Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's
by Zacks Equity Research
Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.